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Abstract 
 
Recently it was discovered that platinum iminoether and amidine complexes have a high 
inhibitory potency on cancer cell proliferation and viability and probably possess a mechanism of 
action different from classic platinum drugs, as the compounds with trans-configuration are more 
active than cis-isomers.  
 
In this work we investigated related platinum(II) complexes with the structural element 
(guanidine)2PtII, prepared by nucleophilic addition of ammonia to the push-pull nitrile ligands in 
cis- and trans-[PtCl2(RCN)2]  (R = NMe2, NEt2, NC5H10). The neutral complexes cis-1–3 and 
trans-1–3 as well as the cationic complexes cis-4–6 and trans-4–6, which contain ammine instead 
of chloro ligands, were synthesized and characterized by Tyan M. supervised by Prof. Dr. 
Kukushkin V. at the Chemistry department of St. Petersburg University. In the presented work 
we have synthesized cationic guanidine compounds trans-
[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2 (R = NEt2, NC5H10) (trans-7,8) by nucleophilic addition 
of methylamine to cyanamide platinum(II) complexes. These compounds were purified and 
characterized by various physical and chemical methods (elemental analysis, ESI mass 
spectrometry, IR, 1H NMR and 13C{1H} NMR). We have studied the biological activity of the 
entire set of guanidine compounds (cis-1–6 and trans-1–8), using various bioanalytical methods. 
 
Cytotoxic activity of guanidine platinum(II) complexes was determined using the 
colorimetric MTT assay in two human cancer cell lines: CH1 (ovarian carcinoma) and SW480 
(colon cancer). IC50 values of these compounds vary within a broad range of micromolar 
concentrations. We could confirm the expectation that the cytotoxicity of several trans-
configured complexes is higher than that of cis-congeners. The analysis showed that there is a 
correlation between the cytotoxic potency of the compounds and the length of the variable 
residue on the guanidine ligand. Moreover, cytotoxicities of the cationic complexes are mostly 
lower, but in some cases even comparable to those of the corresponding neutral complexes, 
despite the lack of distinctly labile ligands. 
 
In order to figure out whether cytotoxicity correlates with cellular uptake of the 
compounds cellular platinum levels were analyzed by ICP-MS upon treatment of adherent 
SW480 cells. Modified cellular uptake experiments (non-adherent state) were performed 
alternatively to determine the cellular levels of those compounds that have a much stronger 
affinity to the polystyrene of the culture plates than to the cells. 
 
Since the difference in cytotoxic potency between cisplatin and transplatin has been 
ascribed to different capacities of DNA binding, DNA interactions of several compounds were 
studied in order to find hints for the possible reasons for their different activities. For this purpose, 
an electrophoretic mobility shift assay indicating the impact on the secondary structure of 
plasmid DNA in cell-free conditions was employed. Furthermore, DNA platination was 
quantified in treated SW480 cells by ICP-MS. In the latter method platinum concentration was 
measured together with phosphorus concentration to determine amount of platinum relative to the 
nucleotides. The results obtained from the electrophoretic mobility shift assay, cellular uptake 
and DNA platination experiments are consistent with the assumption that DNA is  the main target 
for guanidine platinum(II) complexes. 
Zusammenfassung 
 
In jüngster Zeit wurde entdeckt, dass Platin-Iminoether- und -Amidine-Komplexe ein 
starkes Vermögen, die Proliferation von Krebszellen zu hemmen, und wahrscheinlich einen von 
klassischen Platinverbindungen abweichenden Wirkmechanismus aufweisen, da die 
Verbindungen mit trans-Konfiguration aktiver sind die als die cis-Isomere. 
 
In der vorliegenden Arbeit wurden nahe verwandte Platin(II)-Komplexe mit dem 
Strukturelement (Guanidin)2PtII, welche mittels nukleophiler Addition von Ammoniak an die 
„Push-Pull“-Nitrilliganden in cis- und trans-[PtCl2(RCN)2] (R = NMe2, NEt2, NC5H10) hergestellt 
werden, untersucht. Die neutralen Komplexe cis-1–3 und trans-1–3 sowie die kationischen 
Komplexe cis-4–6 und trans-4–6, welche Ammin- anstelle von Chloro-Liganden enthalten, 
wurden von M. Tyan unter der Betreuung von Prof. Dr. V. Kukushkin am Department für 
Chemie der Universität St. Petersburg, Russland, synthetisiert und charakterisiert. In der 
vorliegenden Arbeit wurden die kationischen Guanidin-Verbindungen trans-
[Pt(NH2Me)2{NH=C(NHMe)NR}2]Cl2 (R = NEt2, NC5H10) (trans-7,8) mittels nukleophiler 
Addition von Methylamin an Cyanamid-Platin(II)-Komplexe synthetisiert. Diese Verbindungen 
wurden gereinigt und mittels verschiedener physikalischer und chemischer Methoden 
(Elementaranalyse, ESI-Massenspektrometrie, IR-Spektroskopie, 1H- und 13C{1H}-NMR-
Spektroskopie) charakterisiert. Die biologische Aktivität wurde an dem gesamten Reihe von 
Guanidin-Verbindungen (cis-1–6, trans-1–8) mittels verschiedener bioanalytischer Methoden 
untersucht. 
 
Die Zytotoxizität der Guanidin-Platin(II)-Komplexe wurde anhand des kolorimetrischen 
MTT-Tests in zwei humanen Krebs-Zellinien bestimmt: CH1 (Ovarialkarzinom) und SW480 
(Kolonkarzinom). Die IC50-Werte dieser Verbindungen variieren in einem großen Bereich 
mikromolarer Konzentrationen. Dabei konnte die Erwartung, dass die Zytotoxizität mehrerer 
trans-konfigurierter Komplexe jene der cis-Analoga übertrifft, bestätigt werden. Weiters wurde 
eine Korrelation zwischen der zytotoxischen Potenz und der Länge des variablen Rests am 
Guanidin-Liganden festgestellt. Die Zytotoxizitäten der kationischen Komplexe sind zwar 
überwiegend geringer, in einigen Fällen aber auch vergleichbar jenen der korrespondierenden 
neutralen Komplexe, trotz des Fehlens ausgesprochen labiler Liganden. 
 
Um herauszufinden, ob die Zytotoxizität mit der zellulären Aufnahme der Verbindungen 
korreliert, wurden die zellulären Platingehalte nach Behandlung von adhärenten SW480-Zellen 
mittels ICP-MS analysiert. Modifizierte Experimente zur zellulären Aufnahme (im nicht-
adhärenten Zustand) wurden alternativ durchgeführt, um auch die zellulären Gehalte jener 
Verbindungen, die eine wesentlich höhere Affinität zum Polystyrol der Kulturplatten als zu den 
Zellen aufweisen, zu bestimmen. 
 
Da der Unterschied der zytotoxischen Potenzen von Cisplatin und Transplatin mit dem 
unterschiedlichen Vermögen, an DNA zu binden, erklärt wird, wurden die DNA-Interaktionen 
mehrerer Verbindungen untersucht, um Hinweise auf mögliche Gründe für die unterschiedlichen 
Aktivitäten zu finden. Für diesen Zweck wurde ein Electrophoretic Mobility Shift Assay, welcher 
die Auswirkung auf die Sekundärstruktur einer Plasmid-DNA unter zellfreien Bedingungen 
veranschaulicht, herangezogen. Weiters wurde das Ausmaß der DNA-Platinierung in behandelten 
SW480-Zellen mittels ICP-MS quantifiziert. Dabei wurden Platin und Phosphor zugleich 
gemessen, um den Gehalt an Platin in Relation zur Anzahl der Nukleotide angeben zu können. 
Die Ergebnisse des Electrophoretic Mobility Shift Assay, der zellulären Aufnahme und der DNA-
Platinierung stehen im Einklang mit der Annahme, dass die DNA das Haupt-Target von 
Guanidin-Platin(II)-Verbindungen ist. 
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1. INTRODUCTION 
 
1.1 Epidemiology of Cancer 
 
Cancer is one of the frequently talked about and most frightening diseases that have 
increased in incedence, rather rapidly, in the past several decades. The disease which was for a 
long time dubbed as the death sentence for the person diagnosed with it has now become more 
manageable, thanks to the fervent efforts of researchers and oncologists. Science has made rapid 
strides to provide many preventive and curative strategies to fight with cancer diseases. 
 
There were about 3.2 million new cases of cancer and 1.7 million deaths from cancer in 
Europe in 2008 (Fig. 1.1). The most common types of cancer disease were colorectal cancer 
(436,000 cases, 13.6% of the total), breast cancer (421,000, 13.1%), lung cancer (391,000, 12.2%) 
and prostate cancer (382,000, 11.9%). The most common death causing cancers were lung cancer 
(342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer 
(129,000, 7.5%) and stomach cancer (117,000, 6.8%) [1].  
 
Around 36,000 people are diagnosed with cancer each year in Austria, with more than 
half being diagnosed with intestinal, lung, breast or prostate cancer. The risk of a person being 
diagnosed with one of these cancers before the age of 75 is approximately 10% in 2010. The risk 
of cancer in general before the age of 75 is as high as 27% and is markedly higher for men than 
for women. 33 in 100 men will be diagnosed with cancer before the age of 75, compared to 22 in 
100 women.  
 
Since 1994, the most common cancer for men has been prostate cancer, with 78.4 cases 
per 100,000 (4,986 cases in absolute terms) in 2007. Previously, the most frequently diagnosed 
cancer was lung cancer. A particularly sharp decline can be seen in malignant neoplasms of the 
stomach, while other types of cancer show fairly small fluctuations or increasing incidence (e.g., 
lymphoma, melanoma). The increase in the annual number of new cases of cancer in men during 
the observation period can be attributed for the most part to the growing number of prostate 
cancers. The most common cancer site in women continues to be breast (www.statistik.at). 
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Figure 1.1. Distribution of the estimated cases and deaths for the 10 most common cancers in 
Europe in 2008. For each sex, the area of the segment of the pie chart reflects the proportion of 
the total number of cases or deaths [1]. 
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 1.2 Carcinogenesis 
 
Cell division is a physiological process that occurs in almost all tissues and under many 
circumstances. Under normal circumstances, the balance between proliferation and programmed 
cell death, usually in the form of apoptosis, is maintained by tightly regulating both processes to 
ensure the integrity of organs and tissues. Mutations in DNA that lead to cancer (only certain 
mutations can lead to cancer and the majority of potential mutations will have no bearing) disrupt 
these orderly processes by disrupting the regulation of these processes. 
 
Carcinogenic mutations results in uncontrolled cell division. The uncontrolled and often 
rapid proliferation of cells can lead to benign tumors first; some of these may turn into malignant 
tumors (cancer) by additional mutations. Benign tumors do not spread to other parts of the body 
or invade other tissues, and they are rarely a threat to life unless they compress vital structures or 
are physiologically active, for instance, producing a hormone. Malignant tumors can invade other 
organs by actively penetrating and destroying the surrounding tissue structures, spread to distant 
locations (metastasis) via the vascular and lymphatic systems and become life-threatening [2]. 
  
More than one mutation is necessary for carcinogenesis. In fact, a series of several 
mutations to certain classes of genes is usually required before a normal cell will transform into a 
cancer cell. Molecular analyses of human tumors carried out in the last decade have revealed that 
the genetic alterations of cancer cells are much more numerous and unstable than previously 
thought [3]. For instance, by sampling colorectal premalignant polyp and carcinoma cell genomes, 
Stoler et al. [4] found that the mean number of genomic changes per carcinoma cell was 
approximately 11,000. In addition, much evidence has accumulated stating that mutations 
(changes in the DNA sequence) are not the only cause of the altered gene expression of cancer 
cells. Epigenetic alterations (heritable and reversible changes other than the DNA sequence) and 
aneuploidy (numerical and structural abnormalities in chromosomes) are common alterations in 
tumor cells, which modify gene expression and may also play a crucial role in carcinogenesis 
[5,6,7]. 
 
It is well known that uncontrolled cell proliferation is the most relevant feature of cancer. 
It is also recognized that the genetic defects of cancer cells result in an altered gene expression 
and in the production of signals that make these cells proliferate in an uncontrolled fashion. 
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Equally important for cell proliferation is that the dividing cell duplicates all its cellular 
components to create two daughter cells [8]. To do this, proliferating cells must take nutrients, 
including micro- and macromolecules from the blood and use them to synthesize all components 
required for the formation of a new cell. Therefore the cellular uptake of different molecules 
including glucose from the blood is required for the synthesis of these macromolecules and 
cellular components (Fig. 1.2). 
 
Figure 1.2. Cancer development requires both DNA alterations and a change in the metabolism. 
The higher rate of cancer cell proliferation leads to an increase in macro- and micro-molecule 
uptake, which may facilitate accumulation of anticancer agents. 
 
On the one hand the increased cellular uptake gives cancer cells an opportunity to divide 
fast; on the other hand it facilitate cancer treatment with metal-based or other therapeutic agents 
due to increased active transport [8,42] and increased membrane fluidity [43]. 
 
Increased 
   uptake 
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1.3 Chemotherapy and Pt-based Therapeutic Agents 
 
Chemotherapy is the general term for any treatment involving the use of chemical agents 
to stop cancer cells from growing. Chemotherapy can eliminate cancer cells at sites remote from 
the primary tumor site. Therefore, chemotherapy is considered a systemic treatment. More than 
half of all people diagnosed with cancer receive chemotherapy. Cancer treatments are tailored to 
the specific needs of the patient. Increasingly, it is common to use several treatments or 
modalities at the same time or in sequence in order to prevent both local recurrence and 
recurrence throughout the body. When modalities are combined to treat cancer, this is referred to 
as a multi-modality treatment. In addition to chemotherapy, other modalities include:  
• surgery (physical removal); 
• radiation therapy (exposure to high energy particle beams); 
• biologicals therapy (monoclonal antibodies); 
• hormonal therapy (interference with hormone-dependent growth); 
• immunomodulating therapy (modulation of immune system, e.g. interferons). 
Chemotherapy works by destroying cancer cells, unfortunately, it cannot tell the 
difference between a cancer cell and some healthy cells. Chemotherapeutic agents frequently 
eliminate not only the fast-growing cancer cells but also other fast-growing normal cells in the 
body, including, hair follicles and hematopoietic cells. An undesirable consequence of 
chemotherapy affecting patient’s body which is not related to the cancer is referred to as a 
complication of treatment, or a side effect. Most of these side effects induced by tolerable doses 
of the drugs are reversible after treatment. Even though a relatively high burden of side effects is 
usually accepted in the treatment of this life-threatening disease, great efforts are being made to 
develop drugs that are better tolerated by the patients. 
In the last several decades many biochemical and molecular biology discoveries have 
been made. These discoveries help to solve the urgent problems of medicine and pharmacology, 
which led to the broad investigations and the development of new industry for novel therapeutic 
agents. The spectrum of currently used chemotherapeutics is extremely wide, one of the main 
streams is the invention of novel metal based drugs which are capable of binding to the most 
common biomolecular targets of the cells – DNA, proteins,  amino acids etc. 
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One of the most interesting classe of substances, which specifically bind to different 
biomolecules of the living cells are the platinum based complexes. Today several platinum based 
drugs are being used in the clinics and play a leading role in cancer chemotherapy all over the 
world.  
 
The most well know and widely spread currently is the neutral complex cis-
diamminedichloroplatinum(II) (CDDP, cisplatin), whose biological activity was discovered by 
Rosenberg B. in 1965 [9]. The principal drawbacks of CDDP are high toxicity, mutagenic effects 
and low selectivity between cancer and normal cells. These shortcomings led to the investigations 
of complexes with platinum and other transition elements [10]. Main goal of current research is 
to synthesize novel substances with a better ratio «cytotoxic activity/side effects».  
 
Right after the discovery of the cytotoxic effect of cisplatin (Fig. 1.3), many laboratories 
all over the world started the investigations of CDDP's structural analogues. Unfortunately very 
few discovered drugs have a better therapeutic index (ratio of antitumour activity/toxicity to the 
patient’s body). One of the most successful drug recently – carboplatin – wins due to fewer side 
effects. 
 
 
Figure 1.3. Clinically approved platinum(II) complexes (cisplatin, carboplatin, oxaliplatin) and 
satraplatin – the platinum(IV) complex being in decisive clinical trials currently.  
oxaliplatin satraplatin 
cisplatin carboplatin 
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The success of cisplatin has imposed a certain direction on the investigation of novel 
substances, in the first instance excluding compounds that may possess a different and probably 
unique mode of action. 
 
Today we know a lot of biologically active compounds which violate the basic «structure 
– activity» relationship announced by Cleare and Hoeschele for platinum based compounds 
[23,29,30,33]. This work, which is devoted to synthesis, characterization and analysis of the 
biological activity of guanidine complexes, whose mode of cytotoxic activity is probably 
different from that of cisplatin, contributes to the knowledge about these non-classic platinum 
drugs. 
 
1.3.1 Pt-based anticancer drugs in clinical use 
 
Cisplatin, carboplatin, and oxaliplatin (Fig. 1.3) are currently the only metal-containing 
antitumor compounds that have broad application in cancer chemotherapy. About 50% of 
chemotherapeutic treatments are based on the application of these complexes. However, 
significant side effects, as well as acquired or intrinsic resistance of cancer cells are the main 
shortcomings of this type of chemotherapy. 
 
In the past several decades a large number of innovative platinum anticancer drugs was 
synthesized. The mechanisms of action of these compounds and their cytotoxic activity were 
investigated in tests in vitro and in vivo. Consistently two main strategies in the synthesis of 
platinum complexes were chosen. The first strategy is the establishment of cytotoxic drugs 
containing ligands exhibiting the specific function of improving tumor selectivity. Thus, these 
compounds are designed to have a selective effect on cancer cells without significant side effects 
on the patient's organism. The second strategy is the development of non-classic platinum 
compounds which do not resemble the structure of cisplatin [12]. 
 
1.3.2 Platinum compounds with improved tumor selectivity 
  
The selectivity against cancer cells can be achieved through several approaches based on 
the differences between normal and cancer cells. One difference arises from the rapid growth of 
cancerous tumors that force the process of angiogenesis to occur in an uncontrolled manner, 
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which leads to defects in the formation of the vascular endothelium. Violation of intercellular 
communication in the vessels causes increased expression of mediators. This leads to increased 
permeability of macromolecules through the blood vessels and the retention of antitumor drugs in 
the area of malignancy (EPR effect) [13]. In order to exploit this effect and to increase the 
accumulation of cytotoxic platinum drugs at the tumour site, macromolecular constructs have 
been synthesised. Some macromolecular copolymers (e.g. AP5280) were already investigated in 
patients [14]. Other examples of such macromolecular constructs are liposomal formations of 
cisplatin (lipoplatin) [15], and oxaliplatin (lipoxal) [16]. 
 
Another approach in cancer treatment is based on targeting of cytotoxic agents using 
organ-specific or receptor-specific carriers. The liver can be nicely targeted by platinum 
complexes containing the residues of galactose [17], or bile acids [18,19] in their structure. On 
one hand the expression of galactose receptors is particularly high on the cytoplasmic membrane 
of parenchymal liver cells and on the other hand the bile acids are synthesized in the liver and 
stored in the gallbladder and therefore have quite strict localization.  
 
Despite the extensive angiogenesis the blood flow to the inner parts of the solid tumors is 
insufficient which leads to hypoxia – oxygen deficiency of large tumors. Therefore, compounds 
that can be reduced in such conditions will be selective to the cancerous tissue. It has been shown 
that the octahedral complexes of platinum(IV) can be reduced to the corresponding planar 
complexes of platinum(II) accompanied by the removal of axial ligands in such conditions. These 
compounds serve as prodrugs – the forerunner of a pharmaceutical agent turning in the active 
drug only inside the tumor [20]. Satraplatin (Fig. 1.3), undergoing the phase III of clinical trials, 
is the most promising compound of this group [21]. Moreover, in contrast to the cisplatin-like 
complexes which can only be introduced intravenously, satraplatin is safe for enteral application. 
 
Due to insufficient supply of growing tumors with oxygen – the cancer cells adopt an 
anaerobic metabolism, which leads to an increase in proton concentration in the intercellular 
space and thus contributes to the lowering of pH (i.e. pH 6.0, with the normal pH 7.4). This 
provides grounds for the directed synthesis of compounds exhibiting cytotoxic activity in a 
weakly acidic environment. One of the most well-known compounds of this type is bis-(O-
dithiocarbonate)-platinum(II) [22].   
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1.3.3 Non-classic platinum complexes as antitumor agents 
 
Two years after cisplatin was established in the clinical trials Cleare and Hoeschele 
investigated a series of platinum complexes and proposed the classic «structure – activity» 
relationship for platinum based drugs [23]:  
1. Platinum complexes must contain 2 (or 1 bidentate) labile ligands, as well as 2 (or 1 bidentate) 
kinetically inert amino-containing ligands;  
2. All the ligands must be coordinated to platinum(II); 
3. Complexes should be neutral and of cis geometry. 
 
According to Cleare and Hoeschele platinum compounds not complying with these 
requirements (non-classic compounds), e.g. trans configured platinum(II) complexes, should be 
less active or do not possess cytotoxic activity. The main target of platinum complexes with any 
geometry is DNA. The difference in cytotoxicity of compounds with various configurations is 
generally due to the form and strength of their adducts to biomolecules. The common prototype 
for non-classic platinum complexes is transplatin (trans-DDP), which possesses lower cytotoxic 
activity in comparison with its structural analogue – cisplatin (Fig. 1.4). This fact is even more 
remarkable because Sadler et al. have shown the increase of transplatin's cytotoxic effect in case 
the treated cells were irradiated with UVA light. The UVA photo–activation results in formation 
of a large number of interstrand DNA adducts, while in the normal conditions only CDDP is 
capable of forming such kind of adducts [24]. 
 
1.3.4 Trans-configured platinum complexes as anticancer drugs 
 
Complexes with iminoether ligands (Fig. 1.4) were investigated thoroughly. It has been 
shown that complexes exhibit significant antitumor activity on leukemia cells and cancerous 
tumors in mice [25]. Moreover, these compounds are capable of forming stable monofunctional 
adducts (with a single strand of DNA helix) with purine DNA bases and thereby stop the DNA 
and RNA polymerases which are of great necessity for gene expression [26]. Promising results 
obtained for complexes with iminoether ligands led to further research in this direction. New 
compounds with other isosteric ligands have been described, e.g. complexes with amidine ligands 
(Fig. 1.4) which are coordinated to platinum with imine nitrogen [27]. 
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Figure 1.4. Trans-configured non-classic platinum(II) complexes. 
  
Currently, considerable attention is devoted to the guanidine platinum complexes. This is 
partly due to the discovery of biological and pharmacological (anticancer) activity of these 
complexes [28]. These compounds also belong to non-classic platinum(II) complexes, as in vitro 
studies have shown that cytotoxic activity of trans-configured complexes is higher than of 
corresponding complexes of cis-geometry. In this work the synthesis of new cationic guanidine 
complexes is reported, together with the analysis of biological activity of trans- and cis-
configured guanidine platinum(II) complexes (Fig. 1.5). 
N
C
NMe2
NH2
H
N
C
NMe2
NH2
H
Pt
Cl
Cl
       
Pt
Cl
Cl
N C
NMe2
NH2
H
NC
NMe2
H2N
H
 
 
Figure 1.5. Guanidine platinum(II) complexes. 
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1.4 Cytotoxicity Analysis 
 
Determination of cytotoxic activity of antitumor agents is conducted usually using a 
colorimetric method with MTT reagent {(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide} used as the dye [36]. 
 
This method is based on the fact that the respiratory chain and electron transport systems 
of the living cells are able to reduce MTT reagent (yellow solution in PBS) to water-insoluble 
formazan (forming purple crystals inside the cells) (Fig. 1.6) [37]. 
NN
N N N
S
Br
    
NHN
N N N
S
 
       
 
Figure 1.6. MTT reduction to formazan crystals under consummation of NADH and the 
corresponding change in color produced by viable cells in the medium. 
 
Purple formazan crystals formed inside living cells are usually dissolved using organic 
solvents such as dimethyl sulfoxide to obtain purple formazan solution (Fig. 1.7). 
 
NADH 
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Figure 1.7. Dissolution of formazan crystals in dimethyl sulfoxide. 
 
The intensity of light absorption of colored solution can be measured with a 
spectrophotometer at a specific wavelength (usually corresponding to the absorption maximum of 
~ 550 nm). The optical densities allow assessing the percentage of living cells in the sample in 
relation to untreated control microcultures. 
 
An alternative method for cytotoxicity testing is based on a different colorimetric method 
using MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) as a dye in presence of phenazine methosulfate (PMS). The main 
difference of this method is that the resulting formazan product produced in the living cells is 
water-soluble and has a maximum absorption at 490–500 nm wavelength in phosphate buffer 
[31]. The main advantages of this method are: the reagent pair MTS + PMS is reduced more 
effectively than its MTT analog forming a water-soluble formazan product, whose level of 
toxicity to the cells is lower than of insoluble crystals (in the case of MTT). The main 
disadvantage of this method is that the reagents are more expensive. 
 
There are methods for determining the number of dead cells (as long as they are not 
degraded), with a use of Trypan Blue as a dye e.g., which selectively stains dead tissues or cells 
in blue color. This substance, which belongs to the azo-dyes (R–N=N–R΄, where R, R΄ – aryl 
groups) is unable to stain living cells, as it can not penetrate through intact plasma membranes, 
but it is easily absorbed by dead cells, because their membranes are damaged. The blue staining 
of dead cells can be observed under the microscope. This method does not depend on the 
metabolic activity of the cells, however, it is very time-consuming, which is limiting factor when 
large number of samples are analyzed [39]. 
DMSO 
Increasing concentration of a drug 
Untreated 
control 
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The reduction of tetrazolium salts (MTT, MTS) to formazan occurs only in living cells. 
Thus, the measurement of the optical density of the samples can be used to determine cell 
viability. However, sometimes different results can be obtained while using these methods, 
because many external factors can lead to the increase or decrease of metabolic activity of living 
cells. Changes in metabolic activity can cause significant fluctuations in optical density parameter, 
while the number of living cells remains unchanged. In this regard, it is important to maintain 
constant favorable conditions (5% CO2 pressure, 37 ºC temperature, humid atmosphere) during 
cells cultivation. The quantity of vital cells is usually expressed in terms of T/C values by 
comparison with untreated control microcultures, and 50% inhibitory concentrations (IC50) are 
calculated from concentration-effect curves by interpolation (Fig. 1.8). 
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Figure 1.8. Concentration-effect curve showing the effect of cis-6 complex on ovarian carcinoma 
cells (CH1). 
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1.5 Aims and Goals 
The neutral compounds cis- and trans-[PtCl2{NH=C(NH2)NR2}2], as well as cationic 
complexes cis- and trans-[Pt(NH3)2{NH=C(NH2)NR2}2](Cl)2 represent promising couples for 
study of biological activity, which includes the investigation of the antitumor activity and the 
determination of the main cellular targets. These compounds are the nitrogen analogues of a new 
class of anticancer drugs based on amidine platinum(II) complexes [21,22,23,41]. 
 
The main aim of this work was the directed synthesis of the cationic guanidine complexes 
trans-[Pt(NH2Me)2{NH=C(NHMe)NR2}2](Cl)2 (R = NEt2 [trans-7], NC5H10 [trans-8]), and the 
determination of the structure–activity relationship for the entire group of guanidine platinum(II) 
complexes (cis-1–6 and trans-1–8). 
 
To achieve the aim several goals were established: 
• To synthesize  new guanidine platinum(II) complexes by metal-mediated nucleophilic 
cyanamide-amino coupling; 
• To analyze the antitumor activity of a whole set of guanidine platinum(II) complexes 
using the MTT assay; 
• To determine whether DNA is one of the main targets of the complexes by means of 
electrophoretic mobility shift assay, cellular uptake and DNA platination experiments. 
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2. MATERIALS AND METHODS 
 
Synthesis. In this work we investigated the biological activity of platinum(II) complexes 
with the structural element (guanidine)2PtII, prepared by nucleophilic addition of ammonia to the 
push-pull nitrile ligands in cis- and trans-[PtCl2(RCN)2]  (R = NMe2, NEt2, NC5H10) platinum(II) 
complexes. Complexes cis-1–6 and trans-1–6 were synthesized and characterized by Tyan M. 
supervised by Prof. Dr. Kukushkin V. at the Chemistry department of St. Petersburg University. 
In addition, we have carried out the nucleophilic addition of methylamine to cyanamide 
platinum(II) complexes (trans-7,8). The products were purified and characterized by various 
physical and chemical methods. We have studied the biological activity of the entire set of 
guanidine compounds (cis-1–6 and trans-1–8), using various bioanalytical methods. 
 
           PtII-mediated cyanamide-amino coupling. The work carried out by Tyan M. showed that 
the absorption of gaseous ammonia solutions by cis-and trans-[PtCl2(RCN)2]  (R = NMe2, NEt2, 
NC5H10) complexes at 20–25 °C for 25–30 min led to the formation of neutral cis-and trans-
[PtCl2{NH=C(NH2)NR2}2] (cis-1–3 and trans-1–3) (Scheme 1, A1, B1) and cationic cis-and 
trans-[Pt(NH3)2{NH=C(NH2)NR2}2](Cl)2 (cis-4–6 and trans-4–6) complexes [11]. All the neutral 
complexes are soluble in DMSO. 
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Individual cationic guanidine complexes cis- and trans--
[Pt(NH3)2{NH=C(NH2)NR2}2](Cl)2 (cis-4–6 and trans-4–6) were obtained due to longer 
amination of initial push-pull platinum(II) complexes for 12 h at room temperature (Scheme 1, A, 
B) and isolated with yields of 73–97%. All the cationic complexes are well soluble in water and 
medium. 
 
List of compounds. cis-1–6 and trans-1–6 complexes prepared by Tyan et al. [11]. 
cis-[PtCl2{NH=C(NH2)NMe2}2] (cis-1) MW = 440.2; solubility: DMSO 
 
N
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N
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cis-[PtCl2{NH=C(NH2)NEt2}2] (cis-2) MW = 496.3; solubility: DMSO, acetone (poor) 
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cis-[PtCl2{NH=C(NH2)NC5H10}2] (cis-3) MW = 520.4; solubility: DMSO, acetone (poor) 
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trans-[PtCl2{NH=C(NH2)NMe2}2] (trans-1) MW = 440.2; solubility: DMSO, acetone (poor) 
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trans-[PtCl2{NH=C(NH2)NEt2}2] (trans-2) MW = 496.3; solubility: DMSO, acetone (poor), 
H2O (poor) 
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trans-[PtCl2{NH=C(NH2)NC5H10}2] (trans-3) MW = 520.4; solubility: DMSO, acetone (poor), 
H2O (poor) 
 
Pt
Cl
Cl
N C
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H
NC
H10C5N
H2N
H
 
 
cis-[Pt(NH3)2{NH=C(NH2)NMe2}2](Cl)2 (cis-4) MW = 474.3; solubility: DMSO, MeOH, EtOH, 
H2O 
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cis-[Pt(NH3)2{NH=C(NH2)NEt2}2](Cl)2 (cis-5) MW = 530.4; solubility: DMSO, MeOH, EtOH, 
H2O 
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cis-[Pt(NH3)2{NH=C(NH2)NC5H10}2](Cl)2 (cis-6) MW = 554.4; solubility: DMSO, MeOH, 
EtOH, H2O 
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trans-[Pt(NH3)2{NH=C(NH2)NMe2}2](Cl)2 (trans-4) MW = 474.3; solubility: DMSO, MeOH, 
EtOH, H2O 
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trans-[Pt(NH3)2{NH=C(NH2)NEt2}2](Cl)2 (trans-5) MW = 530.4; solubility: DMSO, MeOH, 
EtOH, H2O 
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trans-[Pt(NH3)2{NH=C(NH2)NC5H10}2](Cl)2 (trans-6) MW = 554.4; solubility: DMSO, MeOH, 
EtOH, H2O 
Pt
N C
NC5H10
NH2
H
NC
H10C5N
H2N
H
H3N
NH3
(Cl)2
 
 
 
 
 
In continuation of the work, we have synthesized cationic guanidine compounds trans-
[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2 (R = NEt2, NC5H10) (trans-7,8) (Scheme 2, B, B1). 
Initial cyanamide platinum(II) complexes [PtCl2(RCN)2] (R = NEt2; NC5H10) were prepared as a 
mixture of geometric cis- and trans-isomers from K2[PtCl4] and 4 equivalents of the respective 
cyanamides. Cis- and trans-complexes were separated by column chromatography on SiO2 
Merck 60 F254 (eluent: Me2CO:CHCl3 = 1:10, by volume). trans-7,8 were prepared by prolonged 
amination of push-pull platinum(II) complexes with methylamine (10x excess) for 4 h at room 
temperature. Total yield amounted 83–87%. Both novel complexes are well soluble in water and 
medium.  
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Scheme 2 
All the substances were identified and characterized by several physical and chemical 
methods of analysis (see chapter 3.2). 
 
Synthetic and characterization data for trans-7,8 complexes. trans-
[Pt(NH2CH3)2{NH=C(NHCH3)N(C2H5)2}2] (trans-7) Anal. Calcd for C14H40N8Cl2Pt: C, 28.67; 
H, 6.87; N, 19.11. Found: C, 28.42; H, 6.90; N, 19.37. ESI+-MS, m/z: 1137.49 [2M – HCl]+ (calc.: 
1137.51), 551.26 [M – HCl]+ (calc.: 551.27), 520.22  [M – HCl – NH2CH3]+ (calc.: 520.22), 
452.20 [M – 2NH2CH3 – 2HCl]+ (calc.: 452.20), 257.65 1/2[M – 2Cl]2+ (calc.: 257.65).  IR (KBr, 
selected bands, cm−1): 3269 (m), 3194 (m), 3092 (m), ν(N−H); 2970 (m-w), 2936 (m-w), 2888 
(m-w), ν(C−H); 1591 (s), ν(C=N); 1282 (m-w), ν(C−N). 1H NMR [CDCl3, δ]: 7.43 (s, br, H, 
=NH–), 5.58 (s, br, H, –NH–), 4.88 (s, br, 2H, –NH2–), 3.31 (q, 3JHH 6.9 Hz, 4H, –CH2– [in 
NEt2]), 3.01 (d, 3JHH 4.5 Hz, 3H, –CH3 [in NHCH3]), 2.30 (t, 3JHH 6.2 Hz, 3H, –CH3 [in 
NH2CH3]), 1.14 (t, 3JHH 6.9 Hz, 6H, –CH3 [in NEt2]). 13C{1H} NMR [CDCl3, δ]: 164.72 (C=N), 
43.61 (–CH2– [carbons in NEt2]), 33.18, 31.62 (–CH3 [carbons in NHCH3/ NH2CH3] ), 13.53 (–
CH3 [carbons in NEt2]). 
trans-7,8 
Intermediate products 
R      Nos. 
NEt2        7 
NC5H10       8 
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Figure 2.1. Structure of trans-7 complex. 
 
Obtained through prolonged amination of the undried CH2Cl2 solutions (2 mL) of the 
trans-[PtCl2(NCNEt2)2] complex (0.205 mmol; 120 mg) by gaseous methylamine (10x excess) 
for 4–5 h at room temperature led to formation of the cationic trans-
[Pt(NH2CH3)2{NH=C(NHCH3)N(Et)2}2](Cl)2 complex (Fig. 2.1). The color changing of solution 
from yellow to colorless and the precipitation of colorless product was observed. The precipitate 
was isolated by filtration, dried and then analysed thoroughly. The total yield of trans-
[Pt(NH2CH3)2{NH=C(NHCH3)N(C2H5)2}2] amounted to about 87% (125.2 mg). Sol: CHCl3; 
MeOH; H2O. MW = M = 586,5; M0 = 515,5 (MW – 2Cl). 
 
trans-[Pt(NH2CH3)2{NH=C(NHCH3)N(C5H10)}2] (trans-8) Anal. Calcd for 
C16H40N8Cl2Pt: C, 31.47; H, 6.60; N, 18.35. Found: C, 31.14; H, 6.71; N, 18.46. ESI+-MS, m/z: 
1185.49 [2M – HCl]+ (calc.: 1185.50), 575.26 [M – HCl]+ (calc.: 575.27), 544.22  [M – HCl – 
NH2CH3]+ (calc.: 544.22), 538.27 [M – 2HCl]+ (calc.: 538.27), 475.20 [M – 2NH2CH3 – 2HCl – 
H]+ (calc.: 475.20), 269.64 1/2[M– 2Cl]2+ (calc.: 269.65).  IR (KBr, selected bands, cm−1): 3418 
(m), 3277 (m), 3089 (m), ν(N−H); 2936 (m-w), 2854 (m-w), ν(C−H); 1584 (s), ν(C=N); 1256 (m-
w), ν(C−N). 1H NMR [CDCl3, δ]: 7.62 (s, br, H, =NH–), 5.42 (s, br, H, –NH–), 4.81 (s, br, 2H, –
NH2–), 3.22 (s, 4H, α–CH2– [in NC5H10]), 2.95 (d, 3H, –CH3 [in NHCH3]), 2.28 (t, 3H, 3JHH 6.3 
Hz, –CH3 [in NH2CH3]), 1.59 (s, br, 6H, β, γ –CH2– [in NC5H10]). 13C{1H} NMR [CDCl3, δ]: 
166.07 (C=N), 49.55 (α–CH2– [carbons in NC5H10]), 32.96, 31.36 (–CH3 [carbons in NHCH3/ 
NH2CH3] ), 26.10, 24.55 (β, γ –CH2– [carbons in NC5H10]). 
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Figure 2.2. Structure of trans-8 complex. 
 
Obtained through prolonged amination of the undried CH2Cl2 solutions (2 mL) of the 
trans-[PtCl2(NCNC5H10)2] complex (0.213 mmol; 130 mg) by gaseous methylamine (10x excess) 
for 4-5 hours at room temperature led to formation of the cationic trans-
[Pt(NH2CH3)2{NH=C(NHCH3)N(C5H10)}2](Cl)2 complex (Fig. 2.2). The color changing of 
solution from yellow to colorless and the precipitation of colorless product was observed. The 
precipitate was isolated by filtration, dried and then analysed thoroughly. The total yield of trans-
[Pt(NH2CH3)2{NH=C(NHCH3)N(C5H10)}2] amounted to about 83% (135.2 mg). Sol: CHCl3; 
MeOH; H2O. MW = M = 610,53; M0 = M – 2Cl = 539,62. 
 
Solvents were obtained from commercial sources and used without further purification 
and drying. Initial cyanimide platinum(II) complexes [PtCl2(Et2NCN)2] and [PtCl2(C5H10NCN)2] 
were prepared according to published methods [31]. 
 
Nitrogen, Hydrogen and Carbon Analysis was carried out at the Department of Organic 
Chemistry, St. Petersburg State University by burning the substance in a stream of oxygen in the 
device 185V Carbon Hydrogen Nitrogen Analyzer, Hewlett Packard. 
 
Infrared Spectra were recorded on a Shimadzu FTIR-8400S spectrophotometer (range 
4000–400 cm–1). The samples were pelletized with KBr.  
 
  24 
1H NMR and 13C{1H} NMR spectra were measured on a Bruker DPX 400 spectrometer 
at room temperature. Chemical shifts in 1H NMR spectra were measured relatively to the signals 
of the solvent (CDCl3 7.27). Chemical shifts in 13C{1H} NMR spectra were measured relatively 
to the signals of the solvent (CDCl3 77.4). 
 
Electrospray Mass Spectra were recorded on the instrument Bruker micrOTOF, 
equipped with an electrospray ion source type (ESI or ES+). Resolution of the instrument was 
10000 at half of the peak. For the mass spectrometric studies samples were dissolved in MeCN. 
The upper boundary of the solution concentration was 5–15 mg/ml. The resulting solution was 
supplied to the electrospray capillary using a KDScientific syringe pump. The voltage generated 
at the final electrode, and the voltage on the capillary were –500 V and –4500 V (ESI+-MS) or 
3500 V (ESI--MS), respectively. The sample solution flow through the electrospray capillary was 
3 ml/min. The output voltage of the capillary was ± 70 or ± 150 V. ESI+ and ESI- mass spectra 
were recorded in the range 50 to 3000 m/z. Drying gas pressure in the spray was 0.4 bar, flow 
rate and temperature of the drying gas were 4.0 l/min and 180°C, respectively. 
 
Thin Layer Chromatography was performed on Merck 60 F254 aluminum plates with 
inflicted layer of silica gel. 
 
Cell Lines and Cultivation Conditions. The cytotoxicity test was performed on two 
cancer cell lines: CH1 (ovarian carcinoma – cells are more sensitive to cisplatin) and SW480 
(colon carcinoma – cells are more resistant to cisplatin), kindly provided by Lloyd R. Kelland 
(CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK) and Brigitte 
Marian (Institute of Cancer Research, Medical University of Vienna, Austria), respectively. Cell 
monolayer adherent cultures were grown in 75 cm2 culture flasks (Iwaki/Asahi Technoglass, 
Gyouda, Japan) in complete medium [i.e., minimal essential medium supplemented with 10% 
heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine, and 1% 
nonessential amino acids (all purchased from Sigma-Aldrich, Austria)]. Cell cultures were 
incubated at 37 °C in a moist atmosphere containing 5% CO2.  
 
Cytotoxicity in Cancer Cell Lines. Cytotoxic activity of guanidine platinum(II) 
complexes was determined using the colorimetric MTT assay. The cells were collected from 
flasks by trypsinization and seeded into 96-well microculture plates (Iwaki/Asahi Technoglass, 
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Gyouda, Japan) in densities of 1500 (for CH1) and 2500 (for SW480) cells per well. After 24 h 
preincubation of the cells the test compounds were dissolved in complete medium, and 200 µl of 
solution was added per well. Those compounds which were insufficiently soluble in medium 
were dissolved in dimethyl sulfoxide and then diluted not to exceed the concentration of 0.5% 
DMSO in the applied solution. The exact data about the solubility of the substances is presented 
in chapter 3.1. The cells were exposed to test compounds for 96 h. At the end of exposure, drug 
solutions were replaced with 150 µl RPMI 1640 culture medium (supplemented with 10% heat-
inactivated fetal bovine serum and 2 mM L-glutamine) plus 20 µl MTT solution in phosphate-
buffered saline (5 mg/ml). After 4 h incubation the RPMI/MTT mixtures were removed and 
formazan crystals formed in the vital cells were dissolved in 150 µl of dimethyl sulfoxide per 
well. Optical densities were measured at 550 nm wavelength with a microplate reader (Tecan 
Spectra Classic). The quantity of vital cells was expressed in terms of T/C values by comparison 
with untreated control microcultures, and 50% inhibitory concentrations (IC50) were interpolated 
from dose-dependent curves. Evaluation was based on means from at least three independent 
experiments, each comprising at least six microcultures per concentration level [32]. 
 
Electrophoretic Mobility Shift Assay was used to determine the drug-DNA interactions. 
The pPUC19 DNA plasmid (Fermentas, UK) was incubated with test compounds for different 
periods of time (3 h – 15 min). The electrophoresis was performed in 1% agarose gel for 2 h at 80 
V and 55 mA in 1x TBE buffer (0.45 M Tris borate, 0.01 M EDTA, pH 8.3, purchased from 
Eppendorf AG, Germany). PEQLAB electrophoresis chambers were used. The staining was 
performed in EtBr solution in 1x TBE (0.2 µg/ml) for 20 minutes. Images were taken under UVE 
light in the GelDoc-It Imaging System (UVP). 
 
Cellular Uptake Experiments (adhesive state) were performed to determine the 
intracellular drug concentration. Cells were seeded in 6-well plates in a total volume of 2.5 ml 
complete medium in densities about 3 × 105 cells per well. Cell microcultures were incubated at 
37 °C for 24 h prior to exposure to the test compounds. The cell number was determined using 
Trypan Blue staining in parallel microcultures during the 2 h exposure period.  After the exposure 
the medium was removed, cells were washed with PBS and consecutively lyzed with 0.5 ml sub-
boiled HNO3 (conc.) per well for 1 h. Pt concentration was quantified by ICP-MS in presence of 
0.5 µM In standard. Results are based on three independent experiments, each consisting of three 
replicates. The method is thoroughly described in Egger et al. [40]. 
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Cellular Uptake Experiments (non-adherent state) were performed alternatively to 
determine the intracellular concentration of those compounds that have a much stronger affinity 
to the polystyrene of the culture plates than to the cells (in this case, cells can be easily collected 
without the need for measuring adsorption blanks). The cells were harvested from the culture 
flasks, counted and seeded to 15 ml tubes in amounts of approximately 3 × 105 cells per tube 
which corresponds with cell concentration in adhesive state experiments. Cells were exposed to 
the drugs for 2 h immediately after seeding and the samples were shaken carefully every 15 
minutes during the incubation to keep the cells in suspension. After the exposure the cells were 
centrifuged, the medium was removed, cells were washed with PBS and consecutively 
transferred to 1.5 ml tubes where they were lyzed with 0.5 ml sub-boiled HNO3 (conc.) per tube 
for 1 h. Pt concentration was quantified by ICP-MS in the presence of 0.5 µM In standard. 
Results are based on three independent experiments, each consisting of three replicates. 
 
DNA Platination levels were determined as a platinum-phosphorus ratio by ICP-MS in 
the presence of In/Be standard. In order to characterize DNA platination, cells were seeded into 
Petri dishes and grew until 80% confluence, subsequently samples were treated with test drug  in 
10 µM concentration for 24 h. After the exposure cells were washed in TBS (0.0027 M KCl, 
0.137 M NaCl, 0.025 M Tris Base, pH 7.4) and harvested with trypsin. The DNA was extracted 
using lysis buffer (10 mM Tris-HCl, 1 mM EDTA, 20 µg/mL Rnase, 0.2 % Triton X-100, pH 
7.4), precipitated with isopropanol and extensively washed with 70% ethanol. The DNA pellets 
were dried and hydrolyzed in 2% sub-boiled HCl over night at room temperature. 
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3. RESULTS AND DISCUSSION 
3.1 Identification and Characterization of Compounds 
 
Prior to the amination reactions we have synthesized cyanamide platinum(II) complexes: 
[PtCl2(Et2NCN)2] and [PtCl2(C5H10NCN)2]. Cis- and trans- compounds were separated using 
column chromatography on silica gel (SiO2 Merck 60 F254). Stability pre-test of the starting 
compounds was conducted using a two-dimensional chromatography method on aluminum 
Merck 60 F254 plates; also it helped us to select an optimal system for elution. Monitoring of the 
reactions was carried out using the TLC method in the presence of reference substances – the 
original substances in the same conditions. The conclusion about the reaction stage was based on 
the appearance of new spots on TLC plates and the disappearance of initial spots. The TLC 
method helps to indicate the selectivity of the reactions by the number of spots on the plate after 
the elution; it helps to predict the possible geometrical structure of the product due to retention 
indexes, and in some cases the possible application of chromatographic methods for isolation and 
purification of the reaction products [33]. 
 
After the isolation of the products in the solid state the IR spectra were recorded in mid-IR 
range (4000–400 cm-1). We could assess the direction and extent of the reactions due to the 
absence of some characteristic absorption bands of the initial cyanamide complex and the 
appearance of absorption bands specific to the reaction products, and due to relative intensity of 
the bands in the IR spectrum [34]. The characteristic C≡N bands of the initial cyanamide PtII 
complexes are observed in the IR spectrum in the range 2250–2350 cm-1 (Fig. 3.1). 
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Figure 3.1. Mid-range IR-spectrum of  cis-[PtCl2(NCNC5H10)2] complex (KBr). 
 
When the nucleophilic cyanamide-methylamine coupling takes place, a characteristic C=N 
vibration band appears in the range 1700–1500 cm-1 and characteristic bands of the imine 
hydrogen atoms appear at frequencies of 3300–3000 cm-1 in the IR spectrum. One can also 
observe the absence of a characteristic C≡N vibration band in the range of 2350–2250 cm-1 (Fig. 
3.2). 
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Figure 3.2. Mid-range IR-spectrum of trans-7 complex (KBr). 
 
In the ES+ mass spectra characteristic molecular ion peaks and peaks corresponding to the 
fragmentation of the analyzed compounds are observed. The most frequent peaks are [M + Н]+, 
[M + K + 2Н − 2NH3 − Cl]+, [M − NH3 − Cl]+, [M − 2NH3 − 2Cl – H]+, [M – 2Cl – H]+ for the 
reaction products of nucleophilic addition of ammonia and [2M – H]+, [M – H – Cl – NH2Me]+, 
1/2[M – 2Cl]2+ for the reaction products of nucleophilic addition of methylamine. Additionally 
the fragmentation of the complexes with the removal of the ligand and the formation of multiply 
charged ions can occur. However, in practice this happens rarely due to the fact that in the ES+ 
mass spectrometry quite a soft ionization method is used: the ionization runs at atmospheric 
pressure under the influence of the potential difference [35]. 
 
Thus, the methods of IR spectroscopy and ES+ mass spectrometry allow to establish the 
direction of the reactions and to confirm the presence of some fragments in the molecule of the 
product. 
 
In case of high purity of the compounds, we recorded the 1H NMR and 13C{1H} NMR 
spectra. The assignment of signals based on the analysis of chemical shifts and on integration of 
 ν(C−H) 
 ν(N−H)  ν(C=N) 
cm-1 
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signals in the 1H NMR spectrum helps to determine the number of protons of each type and to 
suggest a possible structure and the configuration of the complex. 
 
13C{1H} NMR spectra allow to complete the overall picture with additional structural 
information and to clarify the compound's formula. In the 13C{1H} NMR spectrum we have 
recorded the appearance of the C=N group carbon atom signal, which is typical for the product of 
nucleophilic addition to cyanamide ligands. Changes in chemical shifts corresponding to all 
carbon atom signals of the products were observed. 
 
After the spectroscopic characterization of the substances the elemental analysis (C, H, N) 
was performed. The match of the obtained results with the theoretically calculated, within the 
error of the method, is additional proof of the product’s purity and assumed chemical formula. 
 
In the next chapter more detailed characterization data for the compounds derived from 
cyanamide–methylamine coupling will be presented. Characterization data for the reaction 
products with ammonia have been described in the thesis of Tyan M. and in the related article 
[11]. 
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3.2 Characterization of Novel Cationic Guanidine Platinum(II) Complexes 
 
The composition of trans-7 and trans-8 complexes is consistent with the data of C, H, N 
elemental analysis. ES+ mass spectrometry data was obtained for these compounds (Fig. 3.3). 
 
 
Figure 3.3. Signal of trans-7 complex, corresponding to the quasi-ion [2M - H]+. Calculated (left) 
and recorded using ES+ mass spectrometry method (right). 
 
In the IR spectra trans-7 and trans-8 complexes give average intensity bands 
corresponding to N–H vibrations, which appear at frequencies of 3300–3000 cm-1, and a high 
intensity ν(C=N)  band in the range from 1639 to 1515 cm-1 (Fig. 3.4). 
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Figure 3.4. IR spectrum of the trans-8 complex in the mid-IR range (KBr). 
 
The characteristic feature of trans-7 and trans-8 1HNMR spectra (Fig. 3.5) is the presence 
of three singlets in 1:1:2 ratio at 7.51-7.35 for imine proton (HN=C), at 5.69-5.48 for amide 
proton of guanidine group (HN–Me) and at 5.12-4.69 for amine protons (H2N–Me) of 
methylamine coordinated to platinum, respectively. 
   
  
 
 
 ν(C−H) 
 ν(C=N)  ν(N−H) 
cm-1 
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Figure 3.5. 1H NMR spectrum of trans-7 complex in CDCl3. Solvent peak is marked with *. 
٭ 
. 
H2O 
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In the 13C{1H} NMR spectra of trans-7 and trans-8 compounds the N=C–N carbon atom 
signals are observed in the range 166.85–162.33; these signals are arranged in the characteristic 
area for C=N carbon atoms (Fig. 3.6). 
 
 
 
Figure 3.6. 13C{1H} NMR spectrum of trans-7 complex in CDCl3. The peak of the solvent is 
marked with an asterisk.  
٭ 
C=N 
CH2–CH3 
CH2–CH3 
NH–CH3 
and 
NH2–CH3 
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3.3 Cytotoxic Activity of Guanidine Platinum(II) Complexes 
 
Cytotoxicity tests were performed in vitro on two cancer cell lines (CH1 and SW480). 
The inhibitory potency on cell proliferation and viability was characterized using the 
spectrophotometric MTT method (MTT assay). To compare the activity of different compounds 
the IC50 value was determined. IC50 values for each compound were obtained from three 
independent experiments.  
 
The in vitro antitumor activity of complexes cis-1–6 and trans-1–8 was investigated (Tab. 
1) and structure-activity relationships were inferred from the data. 
 
Table 1. IC50 values (µM; mean ± standard deviation) of complexes cis-1–6 and trans-1–8 on 
two cell lines (CH1 and SW480). 
  CH1 SW480    CH1 SW480 
cis 2.7 ± 0.4 36 ± 2  1 cis 2.7 ± 0.4 36 ± 2 1 
trans 5.2 ± 1.1 36 ± 10  2 cis 3.0 ± 0.4 32 ± 7 
cis 3.0 ± 0.4 32 ± 7  3 cis 4.4 ± 0.8 32 ± 5 2 
trans 23 ± 4 62 ± 5  1 trans 5.2 ± 1.1 36 ± 10 
cis 4.4 ± 0.8 32 ± 5  2 trans 23 ± 4 62 ± 5 3 
trans 7.4 ± 1.3 19 ± 3  3 trans 7.4 ± 1.3 19 ± 3 
cis 21 ± 6 374 ± 40  4 trans 209 ± 65 >640 4 
trans 209 ± 65 >640  5 trans 25 ± 4 111 ± 22 
cis 39 ± 12 42 ± 6  6 trans 8.2 ± 2 55 ± 1 5 
trans 25 ± 4 111 ± 22  4 cis 21 ± 6 374 ± 40 
cis 40 ± 2 46 ± 2  5 cis 39 ± 12 42 ± 6 6 
trans 8.2 ± 2 55 ± 1 6 cis 40 ± 2 46 ± 2 
7 trans 135 ± 42 241 ± 3 7 trans 135 ± 42 241 ± 3 
8 trans 325 ± 58 >640 8 trans 325 ± 58 >640 
cisplatin 0.14 ± 0.03 3.3 ± 0.4 cisplatin 0.14 ±0.03 3.3 ± 0.4 
transplatin 15 ± 2 19 ± 3  transplatin 15 ± 2 19 ± 3 
 
The most interesting relationship is shown for substances trans-4,5,6 (Fig. 3.7). The 
antitumor activity of these compounds correlates with the length of the side residue (IC50 varies 
from 209 µM for R = NMe2 to 8.2 µM for R = NC5H10). Moreover, the cytotoxicity of complex 
trans-6 on the CH1 cells is significantly higher than that of cis-6 (Fig. 3.8). 
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It is also worth mentioning that the most active compound on the SW480 cell line is 
complex trans-3 with the largest side residue R (R = NC5H10, IC50 = 19 µM). Antitumor activity 
of this compound exceeds the corresponding value for the most active complex of cis-
configuration (cis-3,  IC50 = 32 µM) twice (Fig. 3.9). 
 
Taking into account the similarity of the structure of platinum(II) complexes with 
guanidine ligands and cisplatin/transplatin and the cytotoxicity of the latter couple we might 
expect the opposite outcome. Regarding these findings guanidine platinum(II) complexes are 
interesting objects for further investigation. Since the differences in cytotoxic potency between 
cisplatin and transplatin have been ascribed to different capacities of DNA cross-linking, analysis 
of DNA interactions of compounds cis-1,3,4,6 and trans-1,3,4,6,7 was done in order to find hints 
for the possible reasons for their different activities (see section 3.5 and 3.6). 
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Figure 3.7. The relationship between the in vitro antitumor activity of substances trans-4,5,6 and 
the length of the side residue (R = NMe2 in trans-4, NEt2 in trans-5, NC5H10 in trans-6) in CH1 
cells. 
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Figure 3.8. Comparison of cytotoxic activity of compounds trans-6 and cis-6 in CH1 cells;    
IC50 = 8.2 µM (trans-6), IC50 = 40 µM (cis-6). 
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Figure 3.9. Comparison of cytotoxic activity of compounds trans-3 and cis-3 in SW480 cells; 
IC50 = 19 µM (trans-3), IC50 = 312 µM (cis-3). 
  38 
 
The IC50 values of complexes cis-1–6, trans-1–8 were compared with the couple 
cisplatin/transplatin. All the compounds are inferior in activity to cisplatin (IC50 = 0.1 µM for 
CH1 cell line, IC50 = 3.3 µM for SW480 cell line). However, the deviation is not always high, e.g. 
trans-3 (IC50 = 18.6 µM for SW480 cell line, Fig. 3.13). Cytotoxic activity of the majority of the 
samples exceeds or is comparable to that of transplatin (IC50 = 15 µM for CH1 cell line, IC50 = 19 
µM for SW480 cell line, Fig. 3.10–3.13). 
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Figure 3.10. Cytotoxicity of cationic cis- and trans- guanidine complexes in CH1 cells. 
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Figure 3.11. Cytotoxicity of cationic cis- and trans- guanidine complexes in SW480 cells 
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Figure 3.12. Cytotoxicity of neutral cis- and trans- guanidine complexes in CH1 cells 
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Figure 3.13. Cytotoxicity of neutral cis- and trans- guanidine complexes in SW480 cells 
 
3.4 Cellular Uptake Experiments 
 
In order to figure out whether cytotoxicity correlates with cellular uptake of the 
compounds cellular platinum levels were analyzed in treated cells by ICP-MS. Inductively 
coupled plasma mass spectrometry (ICP-MS) is one of the main techniques for sensitive 
qualitative and quantitative analysis of metals and non-metals. The main advantages of this 
method are rapidity, high sensitivity (which is important due to small concentration of some 
substances in the cells), multi-elemental analysis (which is crucial for DNA platination 
experiments where Pt concentration has to be measured together with P concentration to 
determine the amount of platinum relative to the number of nucleotides) and good control of 
interferences. 
 
The total amount of cellular Pt, which is taken up by human cancer SW480 cell line 
during 2 h exposure to a 50 µM of cis-1,3,4,6, trans-1,3,4,6,7, as well as the reference 
compounds was measured using ICP-MS (Fig 3.14). As described by Egger et al. [40] 
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Figure 3.14. Cellular uptake in adherent SW480 cells during 2 h exposure with 50 µM cis- and 
trans-configured Pt complexes. 
 
The dependence of cellular uptake on coordination geometry in the case of neutral 
guanidine complexes (cis-1, cis-3, trans-1, trans-3) correlates well with the reference couple (cis-
DDP, trans-DDP), where trans-configured compounds are taken up more efficiently by the cells. 
For the cationic guanidine complexes (cis-4, cis-6, trans-4, trans-6) the reversed relationship is 
observed. During the experiment with adhesive cell microcultures we faced a problem that some 
of the substances (cis-4, trans-4) had high affinity to the plastics of the dishes. The control wells 
which were exposed to the test substances but were free from cells during all the experiment, 
showed a high concentration of the Pt at ICP-MS detection, meaning that big amount of drug 
must have been absorbed to the well's surface and became desorbed by the preparation.  
 
To overcome the problem we decided to optimize the conditions for these two substances 
and performed the experiment with non-adherent cells. These helped us to avoid desorption of 
adsorbed compounds as we isolated the exposure and lyzing steps from each other using different 
vessels. 
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Cationic Control 
1,4 - R = NMe2 
3,6 - R = NC5H10
7 - R = NEt2
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Figure 3.15. Cellular uptake of compounds cis-4, trans-4 (50 µM, 2 h exposure) in non-adherent 
experiment compared with the cis-DDP/trans-DDP couple in SW480 cells. 
 
The modified experiment showed rather appropriate repeatability and comparatively low 
deviation levels. The values obtained for cis-DDP and trans-DDP correspond well with those 
observed in the adherent state. 
 
To interpret the uptake results several important features common and diverse for the 
cationic and neutral guanidine complexes should be mentioned: 
 
1. On one hand the symmetry of the trans-configured complexes reduces the dipole 
moment of the molecule making them more lipophilic. Thereby neutral trans-compounds possess 
a higher ability to penetrate lipid membranes. On the other hand the dipole moment of cis-
complexes is asymmetric, causing an increase of polarity, lower lipophilicity and lower cellular 
permeability as a consequence. Another important difference between cis- and trans- complexes 
is their three-dimensional geometry. While trans-complexes maintain the planar structure in the 
solution cis-complexes steric hindrance of adjacent ligands can force their rotation out of the 
coordination plane. The planer structure is sterically more favorable for passage through 
membranes which allows the trans-complexes to be taken up more efficiently.  
 
2. Kinetically inert amino-containing ligands of the cationic complexes are very stable 
and can be hardly exchanged with H2O. Recently we can not explain what leads to a higher 
4 - R = NMe2
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lipophilicity and better cellular permeability of cis-configured cationic guanidine complexes in 
comparison with their trans-isomers. 
 
3. Talking about the relationship between different cis-/trans-couples we suggest that the 
permeability of complexes with larger organic side residues is higher due to their pronounced 
lipophilicity which helps them to enter the cells. 
 
3.5 DNA Platination 
 
ICP-MS was used to detect the DNA platination of SW480 cells. Pt concentration was 
measured together with P concentration to determine the amount of  bound platinum relative to 
the number of nucleotides. Based on Pt and phosphorus concentrations the Pt-nucleotide ratio 
was calculated as a measure for the extent of DNA platination. The DNA platination is given in 
comparison with cellular uptake data (Fig. 3.16). 
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Figure 3.16. DNA platination (10 µM, 24 h exposure) and cellular uptake (50 µM, 2 h exposure) 
of cis- and trans-configured Pt complexes in SW480 cells. 
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The cellular uptake of cis-DDP/trans-DDP and cationic guanidine complexes corresponds 
quite well with the DNA platination values, while the trans-configured neutral complexes, which 
were taken up more effectively show lower levels of DNA binding then their cis-congeners. 
 
For cis-configured guanidine complexes higher number of DNA interactions was shown. 
We assume that ligands in cis-position are less shielded and are capable of forming the higher 
number of Pt-DNA adducts. The strength and structure of the adducts differs greatly e.g. lower 
amount of trans-3 complex in the SW480 cells nuclei is more cytotoxic then its cis-isomer (Fig. 
3.10). 
 
3.6 Electrophoretic Mobility Shift Assay 
 
Electrophoretic mobility shift assay was performed for the same set of substances. The 
pUC19 plasmid was exposed to the drugs for different time periods (3 h – 2 h – 1 h – 30 min – 15 
min) and then the mobility of the DNA was studied in the agarose gel. The retardation of the 
supercoiled form plasmid in the gel allows us to judge about the impact of the compounds on 
DNA secondary structure (Fig. 3.17). 
 
 
  
C1   3 h 3 h 2 h   1 h  30’ 15’ C2  C3   2 h    1 h   30’ 15’  M 
C1  3 h 3 h 2 h   1 h  30’  15’ C2  2 h  1 h   30’  15’ 
 M 
cis-1 trans-1 
cis-3 trans-3 
I 
II 
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Figure 3.17 (I–V). Mobility of the plasmid pUC19 after the exposure to 100 µM of different cis-
/trans- configured drugs. C – control, M – marker. Bright bands correspond to the supercoiled 
form of the plasmid, whereas bands of the open circular form are mostly too weak to allow 
interpretation. 
 
From all the tested compounds only trans-4 (Fig. 3.17 IV) does not alter the 
electrophoretic mobility of the plasmid significantly, suggesting that if this compound interacts 
with DNA at all it does so without altering DNA secondary structure, excluding all forms of 
cross-links. This is consistent with the lack of marked cytotoxicity in the MTT assay (Fig. 3.10, 
3.11). All the other drugs are capable of DNA binding in varying degree. Complex trans-3 is also 
remarkable (Fig. 3.17 II), as it is able to bind to DNA such that DNA becomes immobile in the 
electric field and remains in the starting well during the electrophoresis after 3 h exposure with 
the drug. This might be caused by interhelical cross-linking of plasmid molecules to larger 
aggregates which are not able to enter the separation gel. 
 
Remarkably, the cationic complexes trans-5–7 (containing N-donor ligand only) show a 
capacity of altering DNA secondary structure similar to cross-linking compounds, even though 
the lack of readily exchangeable ligands suggests that DNA interaction of these compounds 
should be of an electrostatic kind primarily.  
C1  3 h 3 h 2 h   1 h  30’  15’ C2  C3   2 h    1 h   30’  15’  M 
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Overall, there is no clear correlation between the cytotoxicity and the impact on plasmid 
DNA for most of the drugs concerning both the time required for the shift and the extent of the 
shift. The only clearly observed relationship belongs to the compounds trans-4,5,6, whose 
cytotoxicity increases with the enlargement of the side residue (Fig. 3.10, 3.11, 3.17 III,IV). The 
fastest DNA impact was shown to the most active complex trans-6, while least active substance 
trans-4 does not show any significant impact on the secondary structure of the plasmid DNA. 
 
An interesting pattern was observed simultaneously for several cis- and trans-configured 
complexes (cis-1,3 and trans-5,6). In these cases, the initial shift of the bond becomes reversed 
upon longer exposure. We assume that the explanation of the plasmid DNA retardation pattern 
can be similar to the one described for related platinum complexes by Zorbas-Seifried et al.: 
untwisting of negative supercoils by platinum-DNA adducts can be followed by induction of 
positive supercoils [32]. In general, monofunctional and bifunctional adducts can result in 
retardation of the plasmid DNA due to higher mass,  decrease of positive charge, untwisting of 
the supercoiled form or acceleration of the plasmid DNA due to bending and/or twisting. The 
composite action of all these factors in time can lead to the observed pattern. 
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4. CONCLUSION and OUTLOOK 
 
Novel cis- and trans-configured (guanidine)2PtII complexes have been synthesized and 
characterized by elemental analyses, IR, electrospray ionization mass spectrometry, 1H, 13C  
NMR spectroscopy. We carried out metal-mediated nucleophilic addition of MeNH2 to push-pull 
PtII nitriles with cyanamide ligands R2NCN (R = NEt2, NC5H10). The obtained trans-7,8 
compounds and the previously synthesized guanidine complexes (cis-1–6, trans-1–6) were tested 
for cytotoxic activity. The compounds cis-1–6 and trans-1–8 are promising materials for 
antitumor activity investigation, because they are the nitrogen analogues of a new class of 
potential anticancer drugs based on amidine platinum(II) complexes [29,30]. For several cis-/ 
trans- couples containing larger organic residues, it was reliably shown that the cytotoxic activity 
of trans-complexes is superior to those of corresponding cis-isomers. Moreover, according to the 
article by Scaffidi-Domianello et al. [41] published very recently a similar dependence of 
cytotoxicity on geometric isomerism was observed in the case of bis(oxime)platinum(II) 
complexes [Pt(NH3)2(R2C=NOH)2](NO3)2, where R = Me (7c/7t), Et (8c/8t), and n-Pr (9c/9t). 
These oxime complexes are structurally related to the guanidine complexes investigated here (Fig. 
3.18). The cytotoxicity of these compounds is also comparable and shows a similar pattern (Tab. 
2), as the platinum complexes with larger residues (R = n-Pr, NC5H10) and 4 nitrogen donor 
atoms possess higher antitumor activity in some cases. 
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Figure 3.18. Platinum(II) oxime and guanidine complexes. 
 
Table 2. IC50 values (µM; mean ± standard deviation) of platinum(II) oxime and guanidine 
complexes in CH1 and SW480 cancer cells (exposure time 96 h). 
  
 CH1 SW480    CH1 SW480 
cis 21 ± 6 374 ± 40  7c cis 21 ± 7 567 ± 39 4 
trans 209 ± 65 >640  7t trans 448 ± 180 >1000 
cis 39 ± 12 42 ± 6  8c cis 717 ± 46 >1000 5 
trans 25 ± 4 111 ± 22  8t trans >1000 >1000 
cis 40 ± 2 46 ± 2  9c cis 162 ± 46 >1000 6 
trans 8 ± 2 55 ± 1  9t trans 29 ± 5 350 ± 30 
 
IC50 values of of guanidine compounds (cis-1–6 and trans-1–8), vary within a broad range 
of micromolar concentrations. We could confirm the expectation that the cytotoxicity of several 
trans-configured complexes is higher than that of cis-congeners. The analysis showed that there 
is a correlation between the cytotoxic potency of the compounds and the length of the variable 
residue on the guanidine ligand. Moreover, cytotoxicities of the cationic complexes are mostly 
lower, but in some cases even comparable to those of the corresponding neutral complexes, 
despite the lack of distinctly labile ligands. 
 
Cationic guanidine complexes trans-7,8 – the reaction products of nucleophilic MeNH2 
addition to cyanamides – have shown a rather low level of in vitro antitumor activity (IC50 = 135 
µM, IC50 = 325 µM on CH1 cells). Based on MTT assay (Fig. 3.10), cellular uptake (Fig. 3.14) 
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and DNA platination (Fig. 3.16) results. The low cytotoxicity of trans-7 may be explained by the 
weak impact on DNA, as observed in the electrophoretic mobility shift assay, which may be due 
to sterical difficulties in interacting with DNA, rather than by the extent of cellular uptake, which 
is similar to both the weakly cytotoxic trans-4 and the much cytotoxic trans-6. 
 
Further investigations of drug-DNA interactions and other potential intracellular targets 
could shed some light on the mode of action of these complexes. Overall, the results obtained 
from the electrophoretic mobility shift assay, cellular uptake and platination experiments are 
consistent with the assumption that DNA is the main target for guanidine platinum(II) complexes. 
 
Our further research can be devoted to expanding the family of (guanidine)2PtII complexes 
by appropriate derivatization. Their DNA interactions can be further characterized as well as 
studied in cells by means of the Comet Assay, and their subcellular distribution can be studied by 
the promising method of Secondary Ion Mass Spectrometry, which allows to observe the 
subcellular PtII distribution on a (sub)micrometer scale. 
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